SIETES :: 92006 citas

Resultados de la búsqueda por SESGO DE PUBLICACIÓN REFINAR BÚSQUEDA

1.

Cruz ML, Xu J, Kashoki M, Lurie P. Publication and reporting of the results of postmarket studies for drugs required by the US Food and Drug Administration, 2009 to 2013. JAMA Intern Med 2017;177:1207-10. [Ref.ID 102016]

2.

Goldacre B, Lane S, Mahtani KR, Heneghan C, Onakpoya I, Bushfield I, Smeeth L. Pharmaceutical companies’ policies on access to trial data, results, and methods: audit study. BMJ 2017;358:j3334. [Ref.ID 101997]

3.

Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266. [Ref.ID 101981]

4.

Goldacre B. The WHO joint statement from funders on trials transparency. BMJ 2017;357:j2816. [Ref.ID 101660]

5.

Baudard M, Yavchitz A, Ravaud P, Perrodeau E, Boutron I. Impact of searching clinical trial registries in systematic reviews of pharmaceutical treatments: methodological systematic review and reanalysis of meta-analyses. BMJ 2017;356:j448. [Ref.ID 101539]

6.

Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]

7.

Erviti López J, Saiz Fernández LC, Garjón Parra J. Fiabilidad de los ensayos clínicos. El peligroso camino de la desregulación de los medicamentos. Med Clin (Barc) 2016;147:554-7. [Ref.ID 101012]

8.

Anónimo. Results have not been published for almost half of clinical trials conducted by large pharmaceutical companies. DIA Daily 2016:2. [Ref.ID 100877]

9.

Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med 2016;176:1826-33. [Ref.ID 100788]

10.

Golder S , Loke YK , Wright K , Norman G. ) Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review . PLOS Medicine 2016;13:e1002127. [Ref.ID 100696]

11.

Novoa A. ¡Cómo se deben reír los CEOs de las farmacéuticas! Falsedades, “expertos comprados” y gobiernos que aceptan la corrupción de la ciencia. NoGracias 2016:11 de septiembre. [Ref.ID 100655]

12.

Jureidini J. Antidepressants fail, but no cause for therapeutic gloom. Lancet 2016;388:844-5. [Ref.ID 100611]

13.

Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, Murugiah K, Lu DY, Mittal A, Krumholz HM, Hines HH. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ 2016;352:i637. [Ref.ID 100065]

14.

Derry S, Wiffen P, Moore A. Topical nonsteroidal anti-inflammatory drugs for acute musculoskeletal pain. JAMA 2016;315:813-4. [Ref.ID 100022]

15.

Gubar S. Living with cancer: a broken covenant with patients. N Y Times (Print) 2016:1. [Ref.ID 99979]

16.

Jefferson T. Qué hacer ante la desconfianza en los ensayos clínicos publicados. Boletín de Información Farmacoterapéutica de Navarra 2015;23:1-12. [Ref.ID 99656]

17.

Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, Abi-Jaoude E. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015;351:h4320. [Ref.ID 99581]

18.

Dyer O. Drug maker must restart obesity drug study after releasing early data. BMJ 2015;350:h2844. [Ref.ID 99103]

19.

Dyer O. Major publisher retracts 43 papers, alleging fake peer review. BMJ 2015;350:h1783. [Ref.ID 98943]

20.

Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med 2015;372:1031-9. [Ref.ID 98939]